Amgad Mentias1, Mary Vaughan Sarrazin2, Milind Desai3, Samir Kapadia3, Peter Cram4, Saket Girotra2. 1. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA. Electronic address: mentiaa@ccf.org. 2. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA; Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Medical Center, Iowa City, IA. 3. Heart and Vascular institute, Cleveland Clinic Foundation, Cleveland, OH. 4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Patterns of diffusion of TAVR in the United States (U.S.) and its relation to racial disparities in TAVR utilization remain unknown. METHODS: We identified TAVR hospitals in the continental U.S. from 2012-2017 using Medicare database and mapped them to Hospital Referral Regions (HRR). We calculated driving distance from each residential ZIP code to the nearest TAVR hospital and calculated the proportion of the U.S. population, in general and by race, that lived <100 miles driving distance from the nearest TAVR center. Using a discrete time hazard logistic regression model, we examined the association of hospital and HRR variables with the opening of a TAVR program. RESULTS: The number of TAVR hospitals increased from 230 in 2012 to 540 in 2017. The proportion of the U.S. population living <100 miles from nearest TAVR hospital increased from 89.3% in 2012 to 94.5% in 2017. Geographic access improved for all racial and ethnic subgroups: Whites (84.1%-93.6%), Blacks (90.0%- 97.4%), and Hispanics (84.9%-93.7%). Within a HRR, the odds of opening a new TAVR program were higher among teaching hospitals (OR 1.48, 95% CI 1.16-1.88) and hospital bed size (OR 1.44, 95% CI 1.37-1.52). Market-level factors associated with new TAVR programs were proportion of Black (per 1%, OR 0.78, 95% CI 0.69-0.89) and Hispanic (per 1%, OR 0.82, 95% CI 0.75-0.90) residents, the proportion of hospitals within the HRR that already had a TAVR program (per 10%, OR 1.07, 95% CI 1.03-1.11), P <.01 for all. CONCLUSION: The expansion of TAVR programs in the U.S. has been accompanied by an increase in geographic coverage for all racial subgroups. Further study is needed to determine reasons for TAVR underutilization in Blacks and Hispanics.
BACKGROUND: Patterns of diffusion of TAVR in the United States (U.S.) and its relation to racial disparities in TAVR utilization remain unknown. METHODS: We identified TAVR hospitals in the continental U.S. from 2012-2017 using Medicare database and mapped them to Hospital Referral Regions (HRR). We calculated driving distance from each residential ZIP code to the nearest TAVR hospital and calculated the proportion of the U.S. population, in general and by race, that lived <100 miles driving distance from the nearest TAVR center. Using a discrete time hazard logistic regression model, we examined the association of hospital and HRR variables with the opening of a TAVR program. RESULTS: The number of TAVR hospitals increased from 230 in 2012 to 540 in 2017. The proportion of the U.S. population living <100 miles from nearest TAVR hospital increased from 89.3% in 2012 to 94.5% in 2017. Geographic access improved for all racial and ethnic subgroups: Whites (84.1%-93.6%), Blacks (90.0%- 97.4%), and Hispanics (84.9%-93.7%). Within a HRR, the odds of opening a new TAVR program were higher among teaching hospitals (OR 1.48, 95% CI 1.16-1.88) and hospital bed size (OR 1.44, 95% CI 1.37-1.52). Market-level factors associated with new TAVR programs were proportion of Black (per 1%, OR 0.78, 95% CI 0.69-0.89) and Hispanic (per 1%, OR 0.82, 95% CI 0.75-0.90) residents, the proportion of hospitals within the HRR that already had a TAVR program (per 10%, OR 1.07, 95% CI 1.03-1.11), P <.01 for all. CONCLUSION: The expansion of TAVR programs in the U.S. has been accompanied by an increase in geographic coverage for all racial subgroups. Further study is needed to determine reasons for TAVR underutilization in Blacks and Hispanics.
Authors: Sreekanth Vemulapalli; John D Carroll; Michael J Mack; Zhuokai Li; David Dai; Andrzej S Kosinski; Dharam J Kumbhani; Carlos E Ruiz; Vinod H Thourani; George Hanzel; Thomas G Gleason; Howard C Herrmann; Ralph G Brindis; Joseph E Bavaria Journal: N Engl J Med Date: 2019-04-03 Impact factor: 91.245
Authors: Jeffrey J Popma; G Michael Deeb; Steven J Yakubov; Mubashir Mumtaz; Hemal Gada; Daniel O'Hair; Tanvir Bajwa; John C Heiser; William Merhi; Neal S Kleiman; Judah Askew; Paul Sorajja; Joshua Rovin; Stanley J Chetcuti; David H Adams; Paul S Teirstein; George L Zorn; John K Forrest; Didier Tchétché; Jon Resar; Antony Walton; Nicolo Piazza; Basel Ramlawi; Newell Robinson; George Petrossian; Thomas G Gleason; Jae K Oh; Michael J Boulware; Hongyan Qiao; Andrew S Mugglin; Michael J Reardon Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Elizabeth J Brown; Daniel Polsky; Corentin M Barbu; Jane W Seymour; David Grande Journal: Health Aff (Millwood) Date: 2016-08-01 Impact factor: 6.301
Authors: Mohamad Alkhouli; David R Holmes; John D Carroll; Zhuokai Li; Taku Inohara; Andrzej S Kosinski; Molly Szerlip; Vinod H Thourani; Michael J Mack; Sreekanth Vemulapalli Journal: JACC Cardiovasc Interv Date: 2019-05-27 Impact factor: 11.195
Authors: Jason D Wright; Ana I Tergas; June Y Hou; William M Burke; Ling Chen; Jim C Hu; Alfred I Neugut; Cande V Ananth; Dawn L Hershman Journal: JAMA Surg Date: 2016-07-01 Impact factor: 14.766
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245
Authors: Jordan A Brown; Jae H Lee; Margaret Anne Smith; David R Wells; Aaron Barrett; Charles Puelz; John P Vavalle; Boyce E Griffith Journal: Ann Biomed Eng Date: 2022-10-20 Impact factor: 4.219
Authors: Sung Eun Kim; Ryoung-Eun Ko; Soo Jin Na; Chi Ryang Chung; Ki Hong Choi; Darae Kim; Taek Kyu Park; Joo Myung Lee; Young Bin Song; Jin-Oh Choi; Joo-Yong Hahn; Seung-Hyuk Choi; Hyeon-Cheol Gwon; Jeong Hoon Yang Journal: Front Cardiovasc Med Date: 2022-08-03